Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells

Jemal, 2003, Cancer statistics 2003, CA Cancer J Clin, 53, 5, 10.3322/canjclin.53.1.5

Gronberg, 2003, Prostate cancer epidemiology, Lancet, 361, 859, 10.1016/S0140-6736(03)12713-4

Clinton, 1998, Diet, nutrition and prostate cancer, Annu Rev Nutr, 18, 413, 10.1146/annurev.nutr.18.1.413

Boyle, 2003, Epidemiology of prostate cancer, Urol Clin North Am, 30, 209, 10.1016/S0094-0143(02)00181-7

Koivisto, 1998, Androgen receptor gene and hormonal therapy failure of prostate cancer, Am J Pathol, 152, 1

Pilat, 1998, Hormone resistance in prostate cancer, Cancer Metastasis, 17, 373, 10.1023/A:1006166511344

Surh, 2003, Cancer chemoprevention with dietary phytochemicals, Nat Rev Cancer, 3, 768, 10.1038/nrc1189

Nelson, 2003, Unconventional therapy for prostate cancer: good, bad or questionable?, Nat Rev Cancer, 3, 845, 10.1038/nrc1210

Singh, 2004, Prostate cancer prevention by silibinin, Curr Cancer Drug Targets, 4, 1, 10.2174/1568009043481605

Shamsuddin, 1997, IP6: a novel anticancer agent, Life Sci, 61, 343, 10.1016/S0024-3205(97)00092-1

Grases, 2001, Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate, J Nutr Biochem, 12, 595, 10.1016/S0955-2863(01)00178-4

Graces, 2001, Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans, Biofactors, 15, 53, 10.1002/biof.5520150105

Fox, 2002, Phytic acid (IP6), novel broad-spectrum anti -neoplastic agent: a systematic review, Complement Ther Med, 10, 229, 10.1016/S0965-2299(02)00092-4

Shamsuddin, 1996, Novel anticancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines, Anticancer Res, 16, 3287

Shamsuddin, 1998, Up-regulation of the tumor suppressor gene p53 and WAFT gene expression by IP6 in HT-29 human colon carcinoma cell line, Anticancer Res, 18, 1479

Vucenik, 1998, Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo, Anticancer Res, 18, 1377

Shamsuddin, 1992, Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line, Cancer Lett, 64, 195, 10.1016/0304-3835(92)90043-U

Vucenik, 1998, IP6 in treatment of liver cancer: I, IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res, 18, 4043

Huang, 1997, Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3 kinase, Cancer Res, 57, 2873

Shamsuddin, 1995, Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells, Carcinogenesis, 16, 1975, 10.1093/carcin/16.8.1975

Zi, 2000, Impairment of erbBI receptor and fluid phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells, Carcinogenesis, 21, 2225, 10.1093/carcin/21.12.2225

Singh, 2003, Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRbrelated protein -E2F complexes, Carcinogenesis, 24, 555, 10.1093/carcin/24.3.555

Shamsuddin, 1988, Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate, Carcinogenesis, 9, 577, 10.1093/carcin/9.4.577

Shamsuddin, 1989, Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane, Carcinogenesis, 10, 625, 10.1093/carcin/10.3.625

Shamsuddin, 1989, Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice, Carcinogenesis, 10, 1461, 10.1093/carcin/10.8.1461

Shamsuddin, 1999, Mammary tumor inhibition by IP6: a review, Anticancer Res, 19, 3671

Vucenik, 1998, IP6 treatment of liver cancer: II, Intratumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res, 18, 4091

Wattenberg, 1999, Chemoprevention of pulmonary carcinogenesis by myo-inositol, Anticancer Res, 19, 3659

Ishikawa, 1999, Inhibition of skin cancer by IP6 in vivo: initiation-promotion model, Anticancer Res, 19, 3749

Vucenik, 1992, Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplantedand metastatic fibrosarcoma, pilot study, Cancer Lett, 65, 9, 10.1016/0304-3835(92)90206-B

Challa, 1997, Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea, Carcinogenesis, 18, 2023, 10.1093/carcin/18.10.2023

Jenab, 1998, The influence of phytic acid in wheat bran on early biomarkers of colon carcinogenesis, Carcinogenesis, 19, 1087, 10.1093/carcin/19.6.1087

Baten, 1989, Inositol phosphate induced enhancement of natural killer cell activity correlates with tumor suppression, Carcinogenesis, 10, 1595, 10.1093/carcin/10.9.1595

Singh, 2004, In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor, Clin Cancer Res, 10, 244, 10.1158/1078-0432.CCR-1080-3

Vucenik, 1995, Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer, Carcinogenesis, 16, 1055, 10.1093/carcin/16.5.1055

Agarwal, 2000, Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents, Biochem Pharmacol, 60, 1051, 10.1016/S0006-2952(00)00385-3

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Morgan, 1995, Principles of CDK regulation, Nature, 374, 131, 10.1038/374131a0

Hunter, 1994, Cyclins and cancer II: cyclin D and CDK inhibitors come of age, Cell, 79, 573, 10.1016/0092-8674(94)90543-6

Grana, 1995, Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs), Oncogene, 11, 211

Toyoshima, 1994, P27, a novel inhibitor of G1 cyclincdk protein kinase activity, is related to p21, Cell, 78, 67, 10.1016/0092-8674(94)90573-8

Xiong, 1993, P21 is a universal inhibitor of cyclin kinases, Nature, 366, 701, 10.1038/366701a0

Tsai, 1993, The CDK2 kinase is required for the G1 to S transition in mammalian cells, Oncogene, 8, 1593

Singh, 2002, Phytochemicals as cell cycle modulators: a less toxic approach in halting human cancers, Cell Cycle, 1, 156, 10.4161/cc.1.3.117

Weinberg, 1995, The retinoblastoma protein and cell cycle control, Cell, 81, 323, 10.1016/0092-8674(95)90385-2

Paggi, 1996, Retinoblastoma protein family in cell cycle and cancer: a review, J Cell Biochem, 62, 418, 10.1002/(SICI)1097-4644(199609)62:3<418::AID-JCB12>3.0.CO;2-E

Wang, 1994, The retinoblastoma tumor suppressor protein, Adv Cancer Res, 64, 25, 10.1016/S0065-230X(08)60834-9

Oian, 1992, Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding, Mol Cell Biol, 12, 5363, 10.1128/MCB.12.12.5363

Hiebert, 1993, Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression, Mol Cell Biol, 13, 3384, 10.1128/MCB.13.6.3384

Taya, 1997, RB kinase and RB-binding proteins: new points of view, Trends Biochem Sci, 22, 14, 10.1016/S0968-0004(96)10070-0

Shirodkar, 1992, The transcription factor E2F interacts with the retinoblastoma product and a pp107-cyclin A complex in a cell cycle-regulated manner, Cell, 68, 157, 10.1016/0092-8674(92)90214-W

Simile, 2004, Down-regulation of c-myc and cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells, Carcinogenesis, 25, 333, 10.1093/carcin/bgh014

Carson, 1999, Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/protein, Cancer Res, 59, 1449

Lin, 1999, The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells, Cancer Res, 59, 2891

Cory, 2003, The Bcl-2 family: roles in cell survival and oncogenesis, Oncogene, 22, 8590, 10.1038/sj.onc.1207102

Liu, 2003, The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics, Curr Med Chem Anticancer Agents, 3, 217, 10.2174/1568011033482459

Cheng, 2000, The cell cycle inhibitors p21/waft and p27/kips are associated with survival in patients treated by salvage prostatectomy after radiation therapy, Clin Cancer Res, 6, 1896

Philipp-Staheli Payne, 2001, p27/kips: regulation and function of a haplo-insufficient tumor suppressor and its misregulation in cancer, Exp Cell Res, 264, 148, 10.1006/excr.2000.5143

Kibel, 2001, Methylation and mutational analysis of p27/kips in prostate carcinoma, Prostate, 48, 248, 10.1002/pros.1104

Piva, 1999, Proteosome-dependent degradation of p27/kips in gliomas, J Neuropathol Exp Neurol, 58, 691, 10.1097/00005072-199907000-00002

Vlach, 1997, Phosphorylation-dependent degradation of cyclin-dependent kinase inhibitor p27, EMBO J, 16, 5334, 10.1093/emboj/16.17.5334

Nguyen, 1999, Cell-free degradation of p27/ kips, a G1 cyclin-dependent kinase inhibitor, is dependent on cdk2 activity and the proteosome, Mol Cell Biol, 19, 1190, 10.1128/MCB.19.2.1190

Katner, 2002, Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27/ kips, Prostate, 53, 77, 10.1002/pros.10124

Joshi, 1998, Inhibition of tumor cell growth by p21 WAFT adenoviral gene transfer in lung cancer, Cancer Gene Ther, 5, 183

Yang, 1995, The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo, Nat Med, 1, 1052, 10.1038/nm1095-1052

Joshi, 1998, Inhibition of pancreatic tumor cell growth in culture by p21 WAFT recombinant adenovirus, Pancreas, 16, 107, 10.1097/00006676-199803000-00001

Eastham, 1995, In vivo gene therapy with p53 or p21 adenovirus for prostate cancer, Cancer Res, 55, 5151

Chen, 1995, Tumor suppression by p21 WAF1, Cancer Res, 55, 4536

Meikrantz, 1995, Apoptosis and the cell cycle, J Cell Biochem, 58, 160, 10.1002/jcb.240580205

Meikrantz, 1994, Activation of cyclin A-dependent protein kinases during apoptosis, Proc Natl Acad Sci USA, 91, 3754, 10.1073/pnas.91.9.3754

Craig, 1997, A recombinant adenovirus expressing p27/kips induces cell arrest and loss of cyclin-cdk activity in human breast cancer cells, Oncogene, 14, 2283, 10.1038/sj.onc.1201064

Chinery, 1997, Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta, Nat Med, 3, 1233, 10.1038/nm1197-1233

Bai, 1998, Promoter activation and following induction of the p211WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells, FEES Lett, 437, 61, 10.1016/S0014-5793(98)01198-3

Katner, 2002, A recombinant adenovirus expressing p27/kips induces cell cycle arrest and apoptosis in human 786-0 renal carcinoma cells, J Urol, 168, 766, 10.1016/S0022-5347(05)64742-8

Katayose, 1997, Promotion of apoptosis: a novel activity associated with the cyclindependent kinase inhibitor p27, Cancer Res, 57, 5441

Wang, 2003, Experimental therapy of human prostate cancer by inhibiting MDM-2 expression with novel mixed backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms, Prostate, 54, 194, 10.1002/pros.10187

Wang, 2001, Overexpressed androgen-receptor linked to p21 WAFT silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line, Cancer Res, 61, 7544

Costantini, 2000, Mitochondrion as a novel target of anticancer chemotherapy, J Natl Cancer Inst, 92, 1042, 10.1093/jnci/92.13.1042

Kulik, 1997, Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt, Mol Cell Biol, 17, 1595, 10.1128/MCB.17.3.1595

Franke, 1997, PI3K: downstream AKTion blocks apoptosis, Cell, 88, 435, 10.1016/S0092-8674(00)81883-8

Bondeva, 1998, Bifurcation of lipid and protein kinase signals of PI3Kgamma to protein kinases PKB and MAPK, Science, 282, 293, 10.1126/science.282.5387.293

Cantley, 1999, New insight into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathways, Proc Natl Acad Sci USA, 96, 4240, 10.1073/pnas.96.8.4240

Levitzki, 1995, Tyrosine kinase inhibition: an approach to drug development, Science, 267, 1782, 10.1126/science.7892601

Roymans, 2001, Phosphatidylinositol 3-kinases in tumor progression, Eur J Biochem, 268, 487, 10.1046/j.1432-1327.2001.01936.x

Testa, 2001, Akt plays a central role in tumorigenesis, Proc Natl Acad Sci USA, 98, 10983, 10.1073/pnas.211430998

Collado, 2000, Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kipl, J Biol Chem, 275, 21960, 10.1074/jbc.M000759200

Datta, 1999, Cellular survival: a play in three Akts, Genes Dev, 13, 2905, 10.1101/gad.13.22.2905